Evidence map›Paper›PMID 33383619›Full record

ArticleViruses2020

Chloroquine and Sulfadoxine Derivatives Inhibit ZIKV Replication in Cervical Cells.

Audrien Alves Andrade de Souza, Lauana Ribas Torres, Lyana Rodrigues Pinto Lima Capobianco, Vanessa Salete de Paula, Cynthia Machado Cascabulho, Kelly Salomão, Maria da Gloria Bonecini-Almeida, Maria de Lourdes Garcia Ferreira, Nubia Boechat, Luiz Carlos da Silva Pinheiro and 1 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Audrien Alves Andrade de SouzaLaboratório de Virologia Molecular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.
Lauana Ribas TorresLaboratório de Virologia Molecular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.
Lyana Rodrigues Pinto Lima CapobiancoLaboratório de Virologia Molecular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.
Vanessa Salete de PaulaLaboratório de Virologia Molecular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.
Cynthia Machado CascabulhoLaboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.
Kelly SalomãoLaboratório de Biologia Celular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.ORCID 0000-0001-5397-718X
Maria da Gloria Bonecini-AlmeidaLaboratório de Imunologia e Imunogenética em Doenças Infecciosas, Instituto Nacional de Infectologia Evandro Chagas/FIOCRUZ, Rio de Janeiro, RJ 21040-360 Brazil.
Maria de Lourdes Garcia FerreiraLaboratório de Síntese de Fármacos, Instituto de Tecnologia em Fármacos, Farmanguinhos-FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.
Nubia BoechatLaboratório de Síntese de Fármacos, Instituto de Tecnologia em Fármacos, Farmanguinhos-FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.ORCID 0000-0003-0146-2218
Luiz Carlos da Silva PinheiroLaboratório de Síntese de Fármacos, Instituto de Tecnologia em Fármacos, Farmanguinhos-FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.ORCID 0000-0002-6398-7717
Elen Mello de SouzaLaboratório de Virologia Molecular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, RJ 21040-360, Brazil.ORCID 0000-0001-6512-6542
Fundação Oswaldo Cruz · BRInstituto Evandro Chagas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the severe morbidity caused by Zika fever, its specific treatment is still a challenge for public health. Several research groups have investigated the drug repurposing of chloroquine. However, the highly toxic side effect induced by chloroquine paves the way for the improvement of this drug for use in Zika fever clinics. Our aim is to evaluate the anti-Zika virus (ZIKV) effect of hybrid compounds derived from chloroquine and sulfadoxine antimalarial drugs. The antiviral activity of hybrid compounds (C-Sd1 to C-Sd7) was assessed in an in-vitro model of human cervical and Vero cell lines infected with a Brazilian (BR) ZIKV strain. First, we evaluated the cytotoxic effect on cultures treated with up to 200 µM of C-Sds and observed CC

Indexed as

AnimalsAntiviral AgentsCell LineCells, CulturedCell SurvivalChlorocebus aethiopsChloroquineHumansMolecular StructureSulfadoxineVero CellsVirus ReplicationZika VirusZika Virus InfectionAntiviral AgentsChloroquineSulfadoxineantiviral effectchloroquinehuman cervical cellshybrid compoundssulfadoxineZika virus

Identifiers

PMID33383619
PMCPMC7823661
OpenAlexW3116209337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.